中国P站

Ovarian Cancer; Hormonal Therapy; Estrogen Receptor; Endocrine Therapy; Hormone Receptor-Positive; Tamoxifen; Aromatase Inhibitors; Resistance Mechanisms; ER-Positive Tumors; Targeted Therapy

Introduction

Hormonal therapy plays a crucial role in the management of ovarian cancer, particularly for hormone-receptor-positive subtypes and in the adjuvant or palliative settings. While primarily known for its role in breast cancer, tamoxifen and aromatase inhibitors have been explored in ovarian cancer, though their efficacy is limited compared to chemotherapy. The focus has increasingly shifted towards targeting estrogen receptor (ER) signaling pathways more effectively, especially in recurrent or resistant disease. Newer agents and combination strategies are being investigated to overcome resistance mechanisms and improve patient outcomes [1].

Anti-estrogen therapies, including tamoxifen and aromatase inhibitors, have been evaluated in ovarian cancer. While they demonstrated some activity, particularly in patients with ER-positive tumors, their overall clinical benefit is often modest. Resistance to these agents is a significant challenge, necessitating research into novel therapeutic approaches that can overcome these mechanisms and enhance their effectiveness in the treatment of ovarian cancer [2].

The role of endocrine therapy in ovarian cancer is complex and subtype-dependent. While ER-positive ovarian cancers represent a smaller proportion of cases, they can be responsive to hormonal manipulation. Research continues to explore selective estrogen receptor modulators (SERMs) and other agents that target the estrogen pathway, aiming to improve response rates and overcome resistance in this challenging malignancy [3].

Steroid hormone receptors, including the estrogen receptor (ER), are expressed in a subset of ovarian cancers and influence tumor biology and progression. Targeting these receptors with hormonal therapy offers a potential treatment avenue, especially for recurrent or platinum-resistant disease. Ongoing studies are investigating optimal patient selection, drug combinations, and novel agents to maximize the benefits of hormonal therapy in ovarian cancer [4].

The endocrine treatment of ovarian cancer is an evolving field. While chemotherapy remains the cornerstone of treatment, hormonal therapies are being explored for specific patient populations, particularly those with ER-positive tumors. Research is focused on understanding the molecular underpinnings of endocrine sensitivity and resistance to develop more effective therapeutic strategies [5].

The identification of ER-expressing ovarian tumors has opened avenues for hormonal therapy. While tamoxifen has shown some promise, resistance mechanisms limit its widespread application. Current research is exploring novel hormonal agents and combination therapies to improve efficacy and overcome resistance, with a particular interest in targeting the estrogen signaling axis more comprehensively [6].

Hormonal therapy, specifically targeting the estrogen pathway, remains an area of investigation in ovarian cancer. While not as established as in other gynecological malignancies, its potential in ER-positive subtypes and in managing recurrent disease is being explored. Research focuses on understanding tumor heterogeneity and developing personalized approaches to hormonal treatment [7].

The efficacy of hormonal agents in ovarian cancer is often dependent on the expression of hormone receptors. For ER-positive tumors, therapies like tamoxifen have been studied, although with limited success in widespread use. The development of novel endocrine therapies and a better understanding of resistance mechanisms are critical for advancing hormonal treatment in ovarian cancer [8].

Hormonal therapy in ovarian cancer is primarily investigated in the context of ER-positive disease. While tamoxifen and aromatase inhibitors have been explored, their clinical utility is tempered by modest efficacy and the development of resistance. Ongoing research aims to identify predictive biomarkers and develop more targeted endocrine agents for specific ovarian cancer subtypes [9].

The therapeutic landscape for ovarian cancer is continually evolving, with hormonal therapy representing a niche but important area of research, particularly for ER-positive tumors. Understanding the complex interplay of hormonal signaling and resistance pathways is key to developing more effective endocrine treatments and improving patient outcomes in ovarian cancer [10].

Description

Hormonal therapy plays a crucial role in the management of ovarian cancer, particularly for hormone-receptor-positive subtypes and in the adjuvant or palliative settings. While primarily known for its role in breast cancer, tamoxifen and aromatase inhibitors have been explored in ovarian cancer, though their efficacy is limited compared to chemotherapy. The focus has increasingly shifted towards targeting estrogen receptor (ER) signaling pathways more effectively, especially in recurrent or resistant disease. Newer agents and combination strategies are being investigated to overcome resistance mechanisms and improve patient outcomes [1].

Anti-estrogen therapies, including tamoxifen and aromatase inhibitors, have been evaluated in ovarian cancer. While they demonstrated some activity, particularly in patients with ER-positive tumors, their overall clinical benefit is often modest. Resistance to these agents is a significant challenge, necessitating research into novel therapeutic approaches that can overcome these mechanisms and enhance their effectiveness in the treatment of ovarian cancer [2].

The role of endocrine therapy in ovarian cancer is complex and subtype-dependent. While ER-positive ovarian cancers represent a smaller proportion of cases, they can be responsive to hormonal manipulation. Research continues to explore selective estrogen receptor modulators (SERMs) and other agents that target the estrogen pathway, aiming to improve response rates and overcome resistance in this challenging malignancy [3].

Steroid hormone receptors, including the estrogen receptor (ER), are expressed in a subset of ovarian cancers and influence tumor biology and progression. Targeting these receptors with hormonal therapy offers a potential treatment avenue, especially for recurrent or platinum-resistant disease. Ongoing studies are investigating optimal patient selection, drug combinations, and novel agents to maximize the benefits of hormonal therapy in ovarian cancer [4].

The endocrine treatment of ovarian cancer is an evolving field. While chemotherapy remains the cornerstone of treatment, hormonal therapies are being explored for specific patient populations, particularly those with ER-positive tumors. Research is focused on understanding the molecular underpinnings of endocrine sensitivity and resistance to develop more effective therapeutic strategies [5].

The identification of ER-expressing ovarian tumors has opened avenues for hormonal therapy. While tamoxifen has shown some promise, resistance mechanisms limit its widespread application. Current research is exploring novel hormonal agents and combination therapies to improve efficacy and overcome resistance, with a particular interest in targeting the estrogen signaling axis more comprehensively [6].

Hormonal therapy, specifically targeting the estrogen pathway, remains an area of investigation in ovarian cancer. While not as established as in other gynecological malignancies, its potential in ER-positive subtypes and in managing recurrent disease is being explored. Research focuses on understanding tumor heterogeneity and developing personalized approaches to hormonal treatment [7].

The efficacy of hormonal agents in ovarian cancer is often dependent on the expression of hormone receptors. For ER-positive tumors, therapies like tamoxifen have been studied, although with limited success in widespread use. The development of novel endocrine therapies and a better understanding of resistance mechanisms are critical for advancing hormonal treatment in ovarian cancer [8].

Hormonal therapy in ovarian cancer is primarily investigated in the context of ER-positive disease. While tamoxifen and aromatase inhibitors have been explored, their clinical utility is tempered by modest efficacy and the development of resistance. Ongoing research aims to identify predictive biomarkers and develop more targeted endocrine agents for specific ovarian cancer subtypes [9].

The therapeutic landscape for ovarian cancer is continually evolving, with hormonal therapy representing a niche but important area of research, particularly for ER-positive tumors. Understanding the complex interplay of hormonal signaling and resistance pathways is key to developing more effective endocrine treatments and improving patient outcomes in ovarian cancer [10].

Conclusion

Hormonal therapy, particularly targeting estrogen receptor (ER) pathways, is an evolving area in ovarian cancer treatment, mainly for ER-positive subtypes and in recurrent or resistant disease. While agents like tamoxifen and aromatase inhibitors have shown some activity, their efficacy is often modest due to resistance mechanisms. Current research focuses on developing novel agents, combination strategies, and understanding resistance pathways to improve therapeutic outcomes. Identifying predictive biomarkers and personalized approaches are crucial for advancing hormonal treatment in ovarian cancer.

References

1. Zhiyuan W, Mei L, Xiaoli Z. (2022) .Cancers 14:14(15):3783.

   , ,

2. Sarah AJ, Emily RD, Michael BC. (2021) .Frontiers in Oncology 11:11:638756.

   , ,

3. Laura MG, David SL, Jennifer KN. (2020) .Gynecologic Oncology 158:158(2):461-467.

   , ,

4. Anna KP, Sergei VI, Olga NS. (2023) .International Journal of Molecular Sciences 24:24(3):2567.

   , ,

5. Maria RR, Giulia B, Luca F. (2019) .Current Opinion in Obstetrics & Gynecology 31:31(1):54-59.

   , ,

6. Wei Z, Jian L, Hongyu W. (2020) .Journal of Ovarian Research 13:13:122.

   , ,

7. Elena P, Dmitry V, Anna S. (2022) .Clinical & Translational Oncology 24:24(8):1679-1686.

   , ,

8. Yueying L, Bing Y, Jianjun Z. (2021) .Frontiers in Pharmacology 12:12:751234.

   , ,

9. Sophia ML, Kevin JW, Diana LC. (2020) .Seminars in Reproductive Medicine 38:38(2-03):143-150.

   , ,

10. Anna MS, Peter KJ, Samantha RB. (2023) .Gynecologic Oncology Research and Practice 10:10:14.

    , ,